Insulin dosing support, inside the workflow

Glucommander® is listed in Epic Connection Hub

View listing →

Epic is a registered trademark of Epic Systems Corporation.

Prepare for the 2026 CMS Mandate with Glytec’s comprehensive guide. Learn More

ATLANTA, Nov. 18, 2026 /PRNewswire/ — Glytec, a leader in inpatient insulin management and metabolic care, announced today that it has been named to TIME Magazine’s list of the World’s Top HealthTech Companies for 2026, which recognizes companies using digital technologies to make healthcare more effective and accessible.

Developed by TIME in partnership with Statista, the ranking evaluates healthcare companies worldwide based on financial performance, reputation analysis, and online engagement. The recognition comes as Glytec builds on more than 20 years of glycemic management expertise to expand its clinical intelligence portfolio across high-cost, high-acuity conditions.

At the center of the company’s innovation is GlytecOne™, a portfolio of clinical solutions designed to improve a health system’s clinical, operational, and financial outcomes. GlytecOne™ includes Glucommander®, Glytec’s FDA-cleared glycemic management system, which has been the industry standard for insulin dosing and inpatient diabetes management for 20 years. Trusted by leading healthcare organizations nationwide, Glucommander® delivers precision-targeted insulin dosing recommendations for patients with diabetes and stress-related hyperglycemia.

TIME World Best Health Tech

The clinical solutions in GlytecOne™ provide an integrated approach to improving metabolic care, connecting clinical intelligence to clinical decisions and workflows. The current solutions in GlytecOne™ address five high-acuity clinical areas in which glucose is a critical  signal: diabetes, sepsis, heart failure, cardiac surgery, and pneumonia. Glucose is the common clinical signal connecting these conditions, serving as the foundation for a new category of care: Metabolic Intelligence. By transforming glucose data into actionable insights across multiple disease states, Glytec enables a more proactive, connected, and intelligent approach to patient care.

By bringing together condition-specific intelligence, workflow integration, and predictive analytics, Glytec empowers care teams to identify at-risk patients sooner, reduce variation in care, and ease the cognitive burden on frontline nurses.

“This recognition from TIME marks a proud moment for our team and reflects the trust hospitals place in Glytec every day,” said Patrick Cua, CEO of Glytec. “We are building on two decades of expertise in insulin management to help care teams recognize risk earlier and act with greater confidence across a broader range of conditions their patients face. Our goal is clear: to help clinicians deliver better care and make their jobs easier.”

About Glytec
Glytec is a healthcare technology and clinical intelligence company dedicated to improving outcomes for high-risk patient populations. Leveraging more than 20 years of leadership in glycemic management, Glytec’s integrated GlytecOne™ system equips hospitals, health systems, and health plans with near-real-time insights and clinical decision support across diabetes, sepsis, heart failure, cardiac surgery, and pneumonia. Its flagship solution, Glucommander®, is an FDA-cleared glycemic management platform that enables safe, more effective insulin management, improving patient outcomes. Through condition-specific solutions spanning admission, inpatient care, discharge, and post-acute follow-up, Glytec helps healthcare organizations improve clinical, operational, and financial performance while advancing the quality of care.

For more information, visit www.glytec.com.

Media Contact
Denise R. Bell
Vice President of Commercial Operations
Glytec, LLC
media@glytec.com
864-370-3297

Book a Discussion

See how your manual glycemic workflows are creating avoidable risk.